Amarin Corp Plc (AMRN)

[Condor64]

The discussion started in connection with trying to think through how much merit is in the generics' argument that they aren't inducing infringement because they aren't encouraging use for 12+ weeks.

It makes sense to me that, because CVD is unquestionably a chronic condition, then a label indicating treatment of CVD would implicitly be encouraging use for 12+ weeks.

Your question ("Is not the treatment of a hypertriglyceride indication always a subset of treatment of any CVD indication?") is a good one I don't know the answer to. If yes, that would be a good fact for AMRN. But doesn't the fact that AMRN's expert admitted to prescribing V for <12 weeks 5% of the time (which led to the finding of no contributory) suggest otherwise in at least some cases?